Has Mehul Desai, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,395,568 in general payments to Mehul Desai, MD across 991 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Mehul Desai, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Mehul Desai, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Mehul Desai, MD

Pain Medicine · Washington, DCNPI 1114045341

Payments from drug & device makers

$1,395,568in general payments, 2019–2025

Across 991 payments — averaging $1408.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

SPR Therapeutics, Inc$530K
Nalu Medical, Inc.$439K
Avanos Medical$123K
Abbott$58K
Medtronic$49K
MML US, Inc.$46K
plus $151K from 34 others

$7,061in research payments, 2019–2025

Across 12 payments — averaging $588.42 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Bioventus LLC$6K
Nevro Corp.$1K

What the payments were for

Consulting fees$223,86766%
Speaking & faculty fees$62,14918%
Travel & lodging$23,9667%
Food & beverage$28,4708%
Entertainment$6170%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
SPR Therapeutics, Inc	67	$529,761
Nalu Medical, Inc.	229	$438,810
Avanos Medical	64	$122,739
Abbott	189	$57,743
Medtronic(2 entities)	155	$48,987
MML US, Inc.	40	$46,037
Stimwave Technologies Incorporated	12	$42,897
Averitas Pharma Inc.	42	$39,003
Seikagaku Corporation	3	$27,021
The Institute Of Musculoskeletal Science And Education	2	$11,150
Relievant Medsystems, Inc.	28	$9,905
Interventional Pain Technologies Inc.	7	$9,338
Vertiflex, Inc.	18	$3,389
Nevro Corp.	23	$2,845
Boston Scientific	25	$1,665
Camber Spine Technologies LLC	5	$669
Bioness Inc	2	$617
Saluda Medical Americas, Inc.	4	$436
Bioventus LLC	7	$352
Spinefrontier, Inc.	4	$342
AbbVie(2 entities)	15	$316
Stryker	3	$231
Vertos Medical, Inc.	3	$216
Brixton Biosciences, Inc.	1	$193
Vertex	6	$171
Zyla Life Sciences, Inc.	15	$142
Stability Biologics, LLC	1	$125
Getinge USA Sales, LLC	1	$90
Tersera Therapeutics LLC	4	$58
Arbor Pharmaceuticals, Inc.	4	$51
Si-bone, Inc.	2	$44
Saol Therapeutics Inc.	1	$43
Globus Medical	1	$36
Pfizer	2	$35
Teva Pharmaceuticals USA, Inc.	1	$26
Collegium Pharmaceutical, Inc.	1	$18
Pacira Pharmaceuticals Incorporated	1	$18
Scilex Pharmaceuticals Inc.	1	$18
Lilly USA, LLC	1	$17
Amgen	1	$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Nalu Neurostimulation System$181,375
INTELLIS ADAPTIVESTIM$35,629
COOLIEF$30,601
SPRINT PNS System$21,390
Intracept$17,994
Vyrsa V1$8,750
COOLIEF* COOLED RADIOFREQUENCY$4,738
GENERATOR$3,082
SYNCHROMED$1,553
INTELLIS$1,479
ReActiv8$1,252
Accurian$1,242
PROCLAIM$753
Stimrouter for pain$617
INCEPTIV$579
Senza Spinal Cord Stimulation System$576
Proclaim Family of SCS IPGs$446
Axium INS DRG IPG$446
SYNCHROMEDII$438
Proclaim IPG$438

How this compares

Too few pain medicine providers in District of Columbiato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024

$464,767

Medicare patients

569

Services billed

2,642

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Tizanidine Hcl	62	$814
Oxycodone Hcl	21	$518
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen	19	$388
Baclofen	18	$276
Cephalexin	13	$203
Gabapentin	20	$119
Hydromorphone Hcl	11	$101
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen	11	$91

Paid to pharmacies, not to this prescriber.

Other pain medicine in Washington

Geet PaulWashington$18K
Raissa Quezado da NobregaWashington$16K
Sina Davari FaridWashington$9K
Knell VillartaWashington$8K
Brent EarlsWashington$7K
Michael Pitts-KieferWashington$6K
May ChinWashington$2K
James PendletonWashington$1K
Julia FrankWashington$1K
Navid RashidWashington$352

See the full list for District of Columbia →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →